Antagonism of dopamine-mediated inhibition in the nigro-striatal pathway: a mode of action of some catatonia-inducing drugs.
D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D002389:Catatonia / Q000139:chemically induced*; D002421:Caudate Nucleus / Q000187:drug effects* / Q000502:physiology; D003864:Depression, Chemical; D004298:Dopamine / Q000008:administration & dosage / Q000494:pharmacology*; D018492:Dopamine Antagonists; D004558:Electric Stimulation; D005260:Female; D006213:Hallucinogens / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D007478:Iontophoresis; D008297:Male; D009433:Neural Inhibition / Q000187:drug effects; D009434:Neural Pathways; D009474:Neurons / Q000187:drug effects*; D010208:Papaverine / Q000494:pharmacology*; D051381:Rats; D013268:Stimulation, Chemical; D013378:Substantia Nigra / Q000187:drug effects* / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects
D000470:Alkaloids; D018492:Dopamine Antagonists; D006213:Hallucinogens; D010208:Papaverine; D004298:Dopamine